Short Interest in Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Grows By 98.7%

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,994,790 shares, an increase of 98.7% from the May 31st total of 1,003,767 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 3 shares, the short-interest ratio is presently 664,930.0 days.

Analyst Ratings Changes

Separately, Zacks Research raised Ono Pharmaceutical to a “hold” rating in a research note on Friday, April 17th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Ono Pharmaceutical currently has a consensus rating of “Hold”.

Ono Pharmaceutical Stock Performance

OTCMKTS OPHLF opened at $13.50 on Wednesday. The stock has a market cap of $6.34 billion, a PE ratio of 13.64 and a beta of 0.32. Ono Pharmaceutical has a 12 month low of $9.20 and a 12 month high of $18.67. The company’s 50-day moving average price is $14.40 and its 200-day moving average price is $14.58. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.